UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

The therapeutic role of interleukin-10 after spinal cord injury

Journal of neurotrauma, 2013-08, Vol.30 (15), p.1311

2013

Link zum Volltext

Verfügbarkeit prüfen

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma

Cancer medicine (Malden, MA), 2019-04, Vol.8 (4), p.1416-1422

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Infectious Disease Consultation on Clinical Management and Mortality in Patients With Candidemia

Clinical infectious diseases, 2019-04, Vol.68 (9), p.1585-1587

2019

Link zum Volltext

Verfügbarkeit prüfen

Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies

Cytotherapy (Oxford, England), 2022-08, Vol.24 (8), p.767-773

2022

Link zum Volltext

Verfügbarkeit prüfen

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells

American journal of hematology, 2022-12, Vol.97 (12), p.1580-1588

2022

Link zum Volltext

Verfügbarkeit prüfen

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis

Annals of internal medicine, 2023-12, Vol.176 (12), p.1625

2023

Link zum Volltext

Verfügbarkeit prüfen

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

JAMA oncology, 2022-05, Vol.8 (5), p.773

2022

Link zum Volltext

Verfügbarkeit prüfen

Infectious Diseases Consultation Is Associated With Decreased Mortality in Enterococcal Bloodstream Infections

Open forum infectious diseases, 2020-03, Vol.7 (3), p.ofaa064-ofaa064

2020

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical assessment of rat nerve isografts and immunosuppressed allografts

Neurological research (New York), 2016-12, Vol.38 (12), p.1094-1101

2016

Link zum Volltext

Verfügbarkeit prüfen

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Blood, 2021-11, Vol.138 (Supplement 1), p.3883-3883

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.95-95

2021

Link zum Volltext

Verfügbarkeit prüfen

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Blood, 2021-11, Vol.138 (Supplement 1), p.1728-1728

2021

Link zum Volltext

Verfügbarkeit prüfen

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20 .19 CAR T‐cells

American journal of hematology, 2022-12, Vol.97 (12), p.1580-1588

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.165-165

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 Trial of Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S10-S11

2022

Link zum Volltext

Verfügbarkeit prüfen

11 - Phase 1/2 Trial of Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S10-S11

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma

Transplantation and cellular therapy, 2022-08, Vol.28 (8), p.487.e1-487.e7

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(8)
Aged
(4)
Hematology
(4)
Immunology
(3)
Male
(3)
Middle Aged
(3)
Adult
(2)
Animals
(2)
Clinical Neurology
(2)
Female
(2)
General & Internal Medicine
(2)
Hematopoietic Stem Cell Transplantation
(2)
Infectious Diseases
(2)
Lymphoma
(2)
Lymphoma, Large B-Cell, Diffuse - Therapy
(2)
Microbiology
(2)
Neoplasm Recurrence, Local
(2)
Neurosciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The therapeutic role of interleukin-10 after spinal cord injury

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma

Impact of Infectious Disease Consultation on Clinical Management and Mortality in Patients With Candidemia

Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Infectious Diseases Consultation Is Associated With Decreased Mortality in Enterococcal Bloodstream Infections

Immunohistochemical assessment of rat nerve isografts and immunosuppressed allografts

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20 .19 CAR T‐cells

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Phase 1/2 Trial of Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

11 - Phase 1/2 Trial of Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

8 - Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) after Chimeric Antigen Receptor T-Cell Therapy Failure

Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) after Chimeric Antigen Receptor T-Cell Therapy Failure

Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma

Suchergebnisse filtern